Author

Carlos R. Becerra

Institution: Hoag Memorial Hospital Presbyterian

Observed institution: Hoag Memorial Hospital Presbyterian

OpenAlex ID: A5130697708

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer

2026 · Benjamin Besse, Vivek Subbiah, et al. · Journal of Clinical Oncology · 4

PP01.36: Efficacy and Safety of Pralsetinib in Patients with Advanced RET Fusion-Positive NSCLC from the United States: A Sub-Analysis of the ARROW Trial

2026 · Vivek Subbiah, Gilberto de Lima Lopes, et al. · Journal of Thoracic Oncology

PP01.33: Efficacy and Safety of Pralsetinib in RET Fusion–Positive NSCLC Previously Treated with Immunotherapy: ARROW Study Sub-Analysis

2026 · Justin F. Gainor, Aaron S. Mansfield, et al. · Journal of Thoracic Oncology

Works count: 3

Citation count: 4

H-index: 1

I10-index: